reported that after 14 weeks of therapy, IBD patients responding to anti-TNF-α treatment exhibited a strong decrease in circulating eNAMPT levels, while non-responders maintained elevated eNAMPT serum concentrations (188), suggesting that eNAMPT might be used as a predictive biomarker in IBD. Here, TNF is linked to irritable bowel syndrome.